FULC
Fulcrum Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 4
Revenue Plunges
RSI Overbought
EPS Below Expectations
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About FULC
Fulcrum Therapeutics, Inc.
A clinical biopharmaceutical company focused on improving the lives of patients with hereditary diseases, especially in the field of rare diseases
26 Landsdowne Street, Cambridge, Massachusetts 02139
--
Fulcrum Therapeutics, Inc., was incorporated in Delaware on August 18, 2015. The company is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases. The company has developed a proprietary product engine that the company uses to systematically identify and validate cellular drug targets that can potentially regulate gene expression to treat the known root causes of genetically defined diseases. The company is using product engines to identify targets that can be drugged by small molecules, regardless of the specific underlying mechanism of gene misexpression. The company has identified drug targets to treat facial muscular dystrophy (FSHD) and certain hemoglobinopathy (i.e. sickle cell disease (SCD)) and the underlying cause of b-thalassemia.
Company Financials
EPS
FULC has released its 2024 Q4 earnings. EPS was reported at -0.31, versus the expected -0.29, missing expectations. The chart below visualizes how FULC has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
